Residency · Residency · Critical Care

Acute Heart Failure and Cardiogenic Shock in the ICU

Definitions and Classification

Acute Heart Failure (AHF)

Acute heart failure is defined as the rapid onset or worsening of symptoms and signs of heart failure requiring urgent evaluation and treatment. The presentation may be de novo, occurring in 25 to 30 percent of cases without a prior heart failure diagnosis and typically precipitated by acute myocardial infarction, myocarditis, or acute valvular disease, or it may represent an acute decompensation of chronic heart failure, which is the most common presentation at 70 to 75 percent. The European Society of Cardiology classification organizes patients into four hemodynamic profiles based on the presence or absence of congestion and hypoperfusion. The warm and wet profile, representing approximately 67 percent of patients, describes adequate peripheral perfusion with volume overload and is managed primarily with diuresis and vasodilators. The cold and wet profile, occurring in approximately 28 percent, describes the combination of hypoperfusion and congestion requiring inotropes in addition to diuresis. The cold and dry profile, comprising approximately 5 percent of cases, describes hypoperfusion without congestion and requires cautious fluid administration and inotropic support. The warm and dry profile represents a compensated state that typically does not require ICU management.

Cardiogenic Shock

Cardiogenic shock is defined by sustained hypotension with a systolic blood pressure below 90 mmHg for more than 30 minutes or the requirement for vasopressor or mechanical circulatory support despite adequate filling pressures, accompanied by evidence of end-organ hypoperfusion manifested by altered mental status, cool and mottled extremities, oliguria, and elevated lactate. The hemodynamic criteria include a cardiac index below 2.2 L/min/m2 and a pulmonary capillary wedge pressure above 15 mmHg. The Society for Cardiovascular Angiography and Interventions classification system stratifies cardiogenic shock into five stages of increasing severity. Stage A represents patients at risk without current signs. Stage B describes the beginning of shock with hypotension or tachycardia but without end-organ dysfunction. Stage C is classic cardiogenic shock requiring vasopressor or inotropic intervention with evidence of hypoperfusion. Stage D describes deterioration despite initial interventions, with escalating support requirements and worsening organ failure. Stage E represents the extremis state with cardiac arrest, refractory to maximal support, and impending death.

Etiologies of Cardiogenic Shock

Acute myocardial infarction accounts for approximately 80 percent of cardiogenic shock, with anterior STEMI being the most common culprit. Mechanical complications of myocardial infarction, including papillary muscle rupture causing acute mitral regurgitation, ventricular septal rupture, and free wall rupture, produce sudden hemodynamic catastrophe requiring emergent surgical intervention. Acute myocarditis from viral etiologies including enterovirus, parvovirus B19, and SARS-CoV-2 can cause severe cardiogenic shock, with giant cell myocarditis representing a particularly aggressive variant that is rapidly fatal without immunosuppressive treatment. Stress cardiomyopathy, or Takotsubo syndrome, produces characteristic apical ballooning that mimics acute coronary syndrome but is typically reversible. Acute valvular disease from endocarditis with acute aortic or mitral regurgitation, prosthetic valve thrombosis, or spontaneous chordal rupture can precipitate cardiogenic shock. End-stage cardiomyopathies of dilated, hypertrophic, and restrictive varieties represent the final pathway of chronic cardiac disease.

<image>Two-by-two grid (Forrester hemodynamic profiles) showing the four clinical profiles of acute heart failure. X-axis: cardiac index (adequate >2.2 L/min/m2 vs. low <2.2). Y-axis: pulmonary capillary wedge pressure (PCWP <18 mmHg vs. >18 mmHg). Quadrant I (warm/dry): normal CI and PCWP — compensated. Quadrant II (warm/wet): normal CI, elevated PCWP — diuretics, vasodilators. Quadrant III (cold/dry): low CI, normal PCWP — cautious fluids, inotropes. Quadrant IV (cold/wet): low CI, elevated PCWP — inotropes + diuretics + vasopressors, consider MCS. Each quadrant includes treatment strategy, mortality percentage, and clinical signs. Overlay the SCAI shock classification stages B-E on the cold/wet quadrant with progressive severity markers.</image>

Diagnostic Workup

Bedside Assessment

The physical examination provides the initial hemodynamic phenotyping that guides management. Signs of congestion include jugular venous distension, hepatojugular reflux, peripheral edema, pulmonary crackles, and an S3 gallop. Signs of hypoperfusion include cool extremities, diaphoresis, altered sensorium, weak pulses, and narrow pulse pressure. Assessment for mechanical complications is critical: a new harsh holosystolic murmur at the left sternal border suggests ventricular septal rupture, while a soft systolic murmur at the apex may indicate acute mitral regurgitation from papillary muscle dysfunction or rupture.

Laboratory Studies

Troponin elevation is expected in acute myocardial infarction and myocarditis and may also be elevated from demand ischemia in any form of shock. BNP above 400 pg/mL or NT-proBNP above 900 pg/mL, adjusted for age, supports the diagnosis of heart failure. Serial lactate measurements serve as the primary marker of tissue hypoperfusion and provide critical guidance for assessing response to therapy. The hepatic function panel may reveal an ischemic hepatitis pattern with AST and ALT elevations exceeding 1000, with a rapid rise and fall characteristic of combined hepatic congestion and hypoperfusion. Renal function assessment must recognize the concept of cardiorenal syndrome, in which rising creatinine during diuresis may reflect hemoconcentration from effective decongestion rather than true kidney injury. Hemolysis markers including LDH and haptoglobin should be monitored in patients with mechanical circulatory support or when thrombotic microangiopathy is suspected.

Echocardiography

Emergent bedside transthoracic echocardiography is the most important diagnostic tool in cardiogenic shock and should be performed within minutes of recognition. The assessment should evaluate left ventricular function including ejection fraction and regional wall motion abnormalities, right ventricular function, valvular disease, and the presence of pericardial effusion. An LVOT velocity-time integral below 10 cm indicates severely reduced cardiac output. Color Doppler assessment can identify acute mitral regurgitation with a flail leaflet or papillary muscle rupture producing an eccentric jet, or ventricular septal defect with flow across the interventricular septum. Right ventricular assessment using TAPSE below 17 mm, RV/LV ratio, and tricuspid annular systolic velocity provides essential information for managing RV-specific shock.

Hemodynamic Assessment

Pulmonary artery catheterization provides definitive differentiation of cardiogenic from distributive shock and guides therapy in complex cases. The classic cardiogenic shock hemodynamic profile demonstrates low cardiac output below 4 L/min, high systemic vascular resistance above 1200 dyn/s/cm5, elevated pulmonary capillary wedge pressure above 18 mmHg, and low mixed venous oxygen saturation below 60 percent. Cardiac power output, calculated as MAP multiplied by cardiac output divided by 451, is the strongest hemodynamic predictor of mortality in cardiogenic shock, with values below 0.6 watts associated with very high mortality. The pulmonary artery pulsatility index, calculated as the difference between systolic and diastolic pulmonary artery pressures divided by the right atrial pressure, identifies right ventricular failure when values fall below 0.9, predicting the need for right ventricular support.

Management of Acute Heart Failure

Volume Management

Intravenous loop diuretics are the cornerstone of volume management. Furosemide is initiated at 1 to 2 times the patient's home oral dose or at 40 to 80 mg intravenously if the patient is diuretic-naive. The DOSE trial of 2011 compared high-dose furosemide at 2.5 times the home dose against low-dose and bolus versus continuous infusion strategies, finding that high-dose treatment trended toward more effective decongestion without significant differences in clinical outcomes. Diuretic resistance should be addressed with sequential nephron blockade by adding a thiazide diuretic such as metolazone at 2.5 to 5 mg orally or chlorothiazide at 500 mg intravenously. The ADVOR trial of 2022 demonstrated that the addition of intravenous acetazolamide at 500 mg daily to loop diuretic therapy improved decongestion rates from 31 to 42 percent at 3 days, though without a mortality difference. The decongestion target is a net negative fluid balance of 1 to 3 liters per day, guided by weight, urine output, clinical assessment of congestion, and BNP trend. A critical concept is that worsening renal function during diuresis may reflect improving decongestion through hemoconcentration rather than true kidney injury, and clinicians should not reflexively discontinue diuretics in response to mild creatinine elevation during otherwise effective decongestion.

Vasodilators

Intravenous nitroglycerin at 5 to 200 mcg/min reduces preload through venodilation and afterload, making it particularly useful in hypertensive acute heart failure with pulmonary edema. Nitroprusside at 0.3 to 5 mcg/kg/min is a potent arterial and venous dilator that should be limited to less than 48 hours due to the risk of cyanide toxicity and avoided in patients with renal or hepatic dysfunction. Nesiritide is no longer recommended following the ASCEND-HF trial demonstrating no benefit with increased hypotension. Vasodilators are contraindicated when the systolic blood pressure is below 90 mmHg or in the setting of cardiogenic shock.

Inotropes (When Needed)

Dobutamine at 2 to 20 mcg/kg/min provides beta-1 mediated inotropy to increase cardiac output but carries risks of tachycardia and arrhythmias. Milrinone at 0.125 to 0.75 mcg/kg/min, a phosphodiesterase III inhibitor, provides both inotropy and vasodilation and is preferred in the setting of right ventricular failure, concurrent beta-blocker use, and pulmonary hypertension. Routine inotrope use should be avoided, as it is associated with increased arrhythmias and mortality as demonstrated in the OPTIME-CHF trial. Inotropes should be used only as a bridge to recovery, a bridge to decision-making, or a bridge to definitive therapy such as mechanical circulatory support or transplant.

Cardiogenic Shock Management

Initial Stabilization

Airway management must be approached cautiously, as the initiation of positive pressure ventilation can worsen hypotension through preload reduction. Vasopressors should be initiated before intubation when possible. Norepinephrine is the first-line vasopressor for cardiogenic shock, supported by the SOAP II trial subgroup analysis demonstrating lower mortality compared to dopamine. Excessive fluid administration should be avoided, as these patients are typically volume-overloaded rather than hypovolemic; small 250 mL boluses should be given only if the patient is clearly hypovolemic based on clinical and hemodynamic assessment. Emergent echocardiography to determine the mechanism of shock is essential for guiding definitive management.

AMI-Related Cardiogenic Shock

Emergent coronary angiography and percutaneous coronary intervention remain the cornerstone of treatment, with a target door-to-balloon time within 90 minutes. The SHOCK trial of 1999 established the mortality benefit of early revascularization over medical stabilization, with 6-month mortality of 50 percent versus 63 percent. The CULPRIT-SHOCK trial of 2017 addressed the question of multivessel PCI versus culprit-only PCI and demonstrated that culprit-lesion-only PCI had lower 30-day mortality and renal replacement therapy rates compared to immediate multivessel PCI at 45 percent versus 55 percent. The current standard is to perform culprit-only PCI initially, with staged revascularization of non-culprit lesions after stabilization.

Mechanical Circulatory Support Escalation

The evidence for mechanical circulatory support has evolved significantly. The IABP-SHOCK II trial demonstrated no mortality benefit for the intra-aortic balloon pump in AMI-related cardiogenic shock, leading to its downgrading from a Class I to a Class IIb or III recommendation. The Impella microaxial flow pump represents a major advancement, with the DanGer Shock trial of 2024 demonstrating that Impella CP reduced 180-day mortality from 59 to 46 percent compared to standard care, representing the first randomized controlled trial to show a mortality benefit for mechanical circulatory support in cardiogenic shock with a number needed to treat of 8. Venoarterial ECMO provides biventricular support at flows of 4 to 6 liters per minute but increases left ventricular afterload, necessitating an LV venting strategy using an IABP, Impella, or atrial septostomy. The ECLS-SHOCK trial of 2023 demonstrated no 30-day mortality difference with VA-ECMO compared to standard care in AMI-related cardiogenic shock, with more complications including limb ischemia and bleeding in the ECMO group.

RV-Specific Cardiogenic Shock

Right ventricular cardiogenic shock, caused by RV infarction, massive pulmonary embolism, acute RV failure in ARDS, or post-LVAD placement, requires a management approach distinct from LV-predominant shock. Preload optimization through cautious fluid challenge with 250 mL boluses is appropriate, but excessive volume must be avoided, as RV distension causes interventricular septal shift that compresses the left ventricle and worsens overall cardiac output. RV afterload reduction with inhaled nitric oxide or epoprostenol, along with avoidance of hypoxia and hypercapnia, is essential. Inotropic support with dobutamine or milrinone, with milrinone preferred for its pulmonary vasodilatory properties, augments RV contractility. Norepinephrine maintains coronary perfusion pressure to the RV. Mechanical support options include the Impella RP, Protek Duo, and VA-ECMO.

<image>Stepwise escalation algorithm for cardiogenic shock management. Top entry: "Cardiogenic shock identified (SCAI Stage C)." First tier: vasopressor (norepinephrine) + inotrope (dobutamine/milrinone) + assess etiology with echo. Second tier: if AMI → emergent cath/PCI (culprit-only). Third tier: SCAI Stage D (deteriorating despite pharmacological support) → mechanical circulatory support decision tree: LV failure → Impella CP (DanGer Shock evidence) or Impella 5.0/5.5; BiV failure → VA-ECMO with LV venting; RV failure → Impella RP or Protek Duo. Fourth tier: SCAI Stage E → evaluate for transplant or durable LVAD candidacy vs. futility/palliative care. Include CPO and PAPi values as decision triggers at each escalation point. Side panel showing contraindications to escalation at each level.</image>

Special Considerations

Cardiorenal Syndrome

Type 1 cardiorenal syndrome, in which acute heart failure precipitates acute kidney injury, is the most relevant variant in the ICU setting. The pathogenesis involves not only reduced renal perfusion from diminished forward flow but also, critically, renal venous congestion from elevated central venous pressure. Current evidence suggests that renal venous congestion may be a more important driver of AKI than reduced renal arterial perfusion. Aggressive decongestion through diuresis frequently improves renal function rather than worsening it. The CARRESS-HF trial demonstrated that mechanical ultrafiltration was not superior to pharmacological diuresis and caused more adverse events. Clinicians should resist the reflex to discontinue diuretics in response to mild creatinine elevation during effective decongestion.

Acute Myocarditis

Fulminant myocarditis, characterized by rapid onset and severe hemodynamic compromise, carries the paradoxical observation that patients supported through the acute phase have better long-term prognosis than those with less dramatic presentations. Giant cell myocarditis is rapidly fatal without immunosuppressive therapy and requires endomyocardial biopsy for definitive diagnosis. Supportive care includes inotropes, vasopressors, and mechanical circulatory support as a bridge to recovery or transplant. NSAIDs should be avoided as they worsen myocardial inflammation in animal models. Immunosuppression is indicated only for giant cell myocarditis or eosinophilic myocarditis and is not recommended for routine viral myocarditis.

Takotsubo (Stress) Cardiomyopathy

Takotsubo cardiomyopathy is triggered by emotional or physical stress and occurs predominantly in postmenopausal women. The classic presentation features apical ballooning with preserved basal function, ST elevation or T-wave inversions, and mildly elevated troponin. Five to 10 percent of patients develop cardiogenic shock, either from the apical variant or from LV outflow tract obstruction in the basal variant. In cases with dynamic LVOT obstruction, inotropes and vasodilators are strictly contraindicated as they worsen the obstruction; management instead requires volume loading, beta-blockers, and phenylephrine. Recovery typically occurs within 1 to 4 weeks, with a recurrence rate of 5 to 10 percent.

Key Clinical Pearls

• Bedside echocardiography is the single most important diagnostic tool in cardiogenic shock — perform within minutes of recognition
• CPO (cardiac power output) is the strongest hemodynamic predictor of mortality in cardiogenic shock — calculate from PAC data
• Norepinephrine is preferred over dopamine as the first-line vasopressor in cardiogenic shock (SOAP II subgroup)
• DanGer Shock is the first RCT demonstrating mortality benefit of MCS (Impella CP) in AMI-cardiogenic shock — a paradigm shift
• Culprit-only PCI is the correct initial strategy in AMI-cardiogenic shock with multivessel disease (CULPRIT-SHOCK)
• VA-ECMO increases LV afterload and requires LV venting — ECLS-SHOCK showed no mortality benefit and more complications
• Do not reflexively stop diuretics for rising creatinine during effective decongestion — venous congestion is the primary driver of cardiorenal syndrome
• Acetazolamide added to loop diuretics improves decongestion in acute heart failure (ADVOR trial)

References

1. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;341(9):625-634.
2. Thiele H, Zeymer U, Thelemann N, et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction. N Engl J Med. 2012;367(14):1287-1296.
3. Moller JE, Engstrom T, Jensen LO, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock (DanGer Shock). N Engl J Med. 2024;390(15):1382-1393.
4. Thiele H, Zeymer U, Akin I, et al. Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med. 2023;389(14):1286-1297.
5. Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387(13):1185-1195.

Read this lecture as Markdown